(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote In favor of Your Favored Shimmering Water - 2NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- 3Revealing the Specialty of Food Matching: Improving Culinary Encounters
- 4Polar bears are rewiring their own genetics to survive a warming climate
- 5Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination
- Finding Your Motivation: Moves toward a Satisfying Life
- 6 Top Computer game Control center
- Want to be better about saving money in 2026? Try these money-saving tips for having a ‘low-buy’ January and beyond
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- Instructions to Clean and Really focus on Your Lab Precious stone
- Brazil approves law strengthening protective measures for female victims of gender-based violence
- VPN Administrations for Online Protection
- The Best 15 Applications for Efficiency and Association
- Giude to Best Web based Learning Stage
